Suppr超能文献

为新发传染病疫苗提供资金。

Funding vaccines for emerging infectious diseases.

机构信息

a Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious Diseases, Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital , Shenzhen , China.

b Special Pathogens Program, National Microbiology Laboratory , Winnipeg , Canada.

出版信息

Hum Vaccin Immunother. 2018 Jul 3;14(7):1760-1762. doi: 10.1080/21645515.2017.1412024. Epub 2018 Jan 16.

Abstract

Immunization has played a large role in substantially reducing the infected and death tolls from infectious diseases. In the case of emerging diseases, the identity of the pathogen responsible, as well as the time and location for the next outbreak, cannot be accurately predicted using current means. Coupled with disjointed efforts towards the development of vaccines and a lack of funds and desire to advance promising products against known emerging pathogens to clinical trials, there has been a shortage of approved products ready for emergency use. Recent outbreaks have exposed these weaknesses, and the Coalition for Epidemic Preparedness Innovations (CEPI) was created in 2016 to address these issues. In this commentary, we discuss the establishment of such a global vaccine fund, and provide some additional points to consider for stimulating further discussion on this comprehensive, ambitious initiative.

摘要

免疫接种在大幅降低传染病感染和死亡人数方面发挥了重要作用。对于新出现的疾病,目前的手段无法准确预测病原体的身份以及下一次爆发的时间和地点。此外,疫苗的开发工作也缺乏协调,资金和推进针对已知新兴病原体的有前途产品进入临床试验的意愿也不足,因此,没有经过批准可用于紧急使用的产品。最近的疫情爆发暴露了这些弱点,为此,流行病防范创新联盟(CEPI)于 2016 年成立,以应对这些问题。在本篇评论中,我们讨论了建立这样一个全球疫苗基金的问题,并提出了一些其他需要考虑的观点,以进一步讨论这一全面而雄心勃勃的倡议。

相似文献

1
Funding vaccines for emerging infectious diseases.
Hum Vaccin Immunother. 2018 Jul 3;14(7):1760-1762. doi: 10.1080/21645515.2017.1412024. Epub 2018 Jan 16.
2
CEPI: Driving Progress Toward Epidemic Preparedness and Response.
Epidemiol Rev. 2019 Jan 31;41(1):28-33. doi: 10.1093/epirev/mxz012.
3
Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus.
Hum Vaccin Immunother. 2017 Dec 2;13(12):2918-2930. doi: 10.1080/21645515.2017.1358325. Epub 2017 Aug 28.
4
Vaccine development for emerging virulent infectious diseases.
Vaccine. 2017 Oct 4;35(41):5437-5443. doi: 10.1016/j.vaccine.2017.02.015. Epub 2017 Feb 16.
5
AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next?
Vaccine. 2017 Aug 16;35(35 Pt A):4470-4474. doi: 10.1016/j.vaccine.2017.04.082. Epub 2017 Jun 19.
6
Vaccines for epidemic infections and the role of CEPI.
Hum Vaccin Immunother. 2017 Dec 2;13(12):2755-2762. doi: 10.1080/21645515.2017.1306615. Epub 2017 Apr 4.
7
Preparing for Emerging Infectious Diseases in the Perinatal Population.
J Obstet Gynecol Neonatal Nurs. 2018 Mar;47(2):245-253. doi: 10.1016/j.jogn.2017.06.005. Epub 2017 Jul 19.
8
Emerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development.
Hum Vaccin Immunother. 2019;15(10):2258-2263. doi: 10.1080/21645515.2019.1634992. Epub 2019 Jul 16.
9
Vaccine innovations for emerging infectious diseases-a symposium report.
Ann N Y Acad Sci. 2020 Feb;1462(1):14-26. doi: 10.1111/nyas.14235. Epub 2019 Oct 28.
10
Outbreak response as an essential component of vaccine development.
Lancet Infect Dis. 2019 Nov;19(11):e399-e403. doi: 10.1016/S1473-3099(19)30305-6. Epub 2019 Jun 27.

引用本文的文献

1
: Unutilized natural medicine and promising future solution to emerging diseases in Africa.
Front Pharmacol. 2022 Aug 22;13:952027. doi: 10.3389/fphar.2022.952027. eCollection 2022.
2
Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies.
J Microbiol. 2022 Mar;60(3):238-246. doi: 10.1007/s12275-022-1547-8. Epub 2022 Jan 28.
5
Developing vaccines against epidemic-prone emerging infectious diseases.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 Jan;63(1):65-73. doi: 10.1007/s00103-019-03061-2.
6
Emerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development.
Hum Vaccin Immunother. 2019;15(10):2258-2263. doi: 10.1080/21645515.2019.1634992. Epub 2019 Jul 16.
7
Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development.
PLoS Negl Trop Dis. 2019 Jan 17;13(1):e0006919. doi: 10.1371/journal.pntd.0006919. eCollection 2019 Jan.

本文引用的文献

1
New Vaccines against Epidemic Infectious Diseases.
N Engl J Med. 2017 Feb 16;376(7):610-613. doi: 10.1056/NEJMp1613577. Epub 2017 Jan 18.
2
Genesis, Evolution and Prevalence of H5N6 Avian Influenza Viruses in China.
Cell Host Microbe. 2016 Dec 14;20(6):810-821. doi: 10.1016/j.chom.2016.10.022. Epub 2016 Dec 1.
3
Role for migratory wild birds in the global spread of avian influenza H5N8.
Science. 2016 Oct 14;354(6309):213-217. doi: 10.1126/science.aaf8852.
4
Establishing a Global Vaccine-Development Fund.
N Engl J Med. 2015 Jul 23;373(4):297-300. doi: 10.1056/NEJMp1506820.
5
The gold industry standard for risk and cost of drug and vaccine development revisited.
Vaccine. 2011 Aug 11;29(35):5846-9. doi: 10.1016/j.vaccine.2011.06.051. Epub 2011 Jun 29.
6
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
Vaccine. 2010 Dec 16;29(2):304-13. doi: 10.1016/j.vaccine.2010.10.037. Epub 2010 Oct 27.
7
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.
Nat Med. 2005 Jul;11(7):786-90. doi: 10.1038/nm1258. Epub 2005 Jun 5.
8
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.
Nature. 2003 Aug 7;424(6949):681-4. doi: 10.1038/nature01876.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验